[Event Report] TXP Medical's Tomoya Osumi Speaks on HEOR at the 5th Ionized Magnesium Study Group

TXP Medical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; Representative Director and CEO: Tomohiro Sonoo; hereinafter 'TXP Medical') announced that Tomoya Osumi, Head of Strategy Promotion and Director of the Medical Data Lab, took the stage at the 5th Ionized Magnesium Study Group hosted by Nova Biomedical to give a lecture on the theme of HEOR (Health Economics and Outcomes Research).

The study group was chaired by Dr. Ken Yamaura, Professor of the Department of Anesthesiology and Resuscitology, Graduate School of Medical Sciences, Kyushu University, and attended by over 100 physicians and clinical laboratory technicians. Vigorous discussions were held regarding the clinical significance and future application possibilities of ionized magnesium measurement.

◾️ Lecture Content

After outlining the background and significance of HEOR, which is becoming increasingly important in recent years, Osumi presented the potential of utilizing medical data from the following perspectives:

- The importance of cost-effectiveness analysis to support the optimal allocation of medical resources. - The advancement of outcome evaluation utilizing Real World Data (RWD). - Specific examples of cost-effectiveness analysis using medical data. - The possibility of an integrated evaluation of clinical and economic value in ionized magnesium measurement.

Furthermore, he introduced analysis case studies utilizing highly standardized laboratory test data from TXP Medical's DWH and structured acute care medical data from the 'NEXT Stage' series. He presented an approach that goes beyond simply grasping laboratory values to simultaneously achieving 'improvement of patient outcomes' and 'enhancement of health economics.'

◾️ Excerpt from the presentation materials

◾️ Participant Feedback

Participants at the venue and online shared comments such as: - 'The perspective of evaluating ionized magnesium measurement from an economic standpoint is novel.' - 'The implementation of HEOR utilizing RWD is indispensable for the future of clinical practice.' These reactions highlighted an opportunity to expand new discussions in this field.

◾️ Future Outlook

TXP Medical will continue to support evidence generation and the visualization of cost-effectiveness for clinical indicators, including ionized magnesium measurement. Concurrently, through the advanced utilization of Real World Data (RWD), we will promote the construction of a framework to comprehensively evaluate clinical utility, health economic validity, and social impact, thereby contributing to the realization of a sustainable healthcare system.

[About TXP Medical]

TXP Medical is a medical data startup founded by active emergency and intensive care physicians with the mission of 'saving lives with medical data.' Based on the acute care medical system 'NEXT Stage ER' introduced in university hospitals and regional core hospitals nationwide, we structure Real World Data (RWD) derived from electronic medical records. We provide clinical research support, fact-finding surveys, and clinical trial support services utilizing over 900 highly standardized laboratory test items and abundant medical record text. With our strength in a network built around large hospitals in the 800-bed class and an expert team of doctors and researchers, we have a track record of collaboration with over 40 companies, including pharmaceutical and medical device manufacturers, supporting problem-solving in diverse disease areas from acute care to rare diseases and oncology.

- Company Name: TXP Medical Co., Ltd. - Location: 2nd Floor, AKIHABARA CENTRAL SQUARE, 3-21-24 Kanda Sakumacho, Chiyoda-ku, Tokyo - Representative: Representative Director and CEO Tomohiro Sonoo (Emergency Medicine Specialist) - Established: August 2017 - Business Description: Acute care data platform, AI technology, RWD utilization services